Abstract
Background: Minimally invasive surgery is now a standard treatment for gastric cancer. Many retrospective studies have reported that robotic gastrectomy is safe and feasible, with similar short- and long-term outcomes as laparoscopic gastrectomy. However, no studies have reported the details of surgical and survival outcomes for robotic gastrectomy. This study aimed to evaluate the surgical trends and techniques of robotic gastrectomy and analyze the surgical outcomes of 2000 consecutive patients with gastric cancer who underwent robotic gastrectomy over 14 years. Methods: Between July 2005 and January 2019, 2000 consecutive robotic gastrectomies were performed. We evaluated short- and long-term outcomes as well as surgical trends after robotic gastrectomy. Results: There were 1,560 subtotal gastrectomies (78%), 324 total gastrectomies (16.2%), 83 proximal gastrectomies (4.2%), and 33 completion total gastrectomies (1.7%). The rates of major complications and mortality were 3.1% and 0.3%, respectively. In a subgroup analysis, there were no significant differences in the rate of complications over time (P = 0.696). Five-year overall survival rates were 97.6% for stage I, 91.9% for stage II, and 69.2% for stage III, with a total recurrence rate of 5.3%. Since its adoption in 2005, the proportion of robotic gastrectomies, as well as technically demanding procedures have increased over time. Conclusions: Our 14 years’ experience of 2000 robotic gastrectomies has shown the proportion, as well as the number of robotic gastrectomies, have tended to increase and trends toward to technically demanding procedures. Outcomes of robotic gastrectomy appear safe and feasible with acceptable short- and long-term outcomes.
Original language | English |
---|---|
Pages (from-to) | 275-286 |
Number of pages | 12 |
Journal | Gastric Cancer |
Volume | 25 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2022 Jan |
Bibliographical note
Funding Information:This study was supported by a grant from the Investigator Sponsored Research Program (ISR-2017-10924), Covidien Private Limited (Medtronic). This funding source played no role in the design of this study and will not play any role in its execution, data analyses and interpretation, or decision to submit results for presentation or publication.
Publisher Copyright:
© 2021, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
All Science Journal Classification (ASJC) codes
- Oncology
- Gastroenterology
- Cancer Research